Cardiff Oncology announces positive colorectal data and $40m stock oversubscription [Yahoo! Finance]
Cardiff Oncology, Inc. (CRDF)
Company Research
Source: Yahoo! Finance
evaluating onvansertib in combination with standard-of-care (SoC) in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC). The Phase II trial (NCT06106308) has a primary endpoint of objective response rate (ORR) and secondary endpoints including progression-free survival (PFS), duration of response (DOR) and safety. There were 30 evaluable patients at the cut-off point (26 November), randomised in a 1:1:1 ratio. A third received 20mg of onvansertib alongside SoC, a third received 30mg alongside SoC and a third received only SoC. The 30mg dose arm demonstrated 64% ORR, compared to 50% in the 20mg arm, and 33% ORR in the control arm. Deeper tumour regression was also noted in the 30mg arm of the study. Fairooz Kabbinavar, chief medical officer of Cardiff Oncology, said of the results: “Our data shows an objective response rate of 64% in patients receiving the 30mg dose of onvansertib in combination with standard of care, significantly higher than the 33% obje
Show less
Read more
Impact Snapshot
Event Time:
CRDF
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRDF alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRDF alerts
High impacting Cardiff Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
CRDF
News
- Cancer Care Disruptions Highlight Growing Demand for Innovative Oncology Treatments [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Cardiff Oncology, Inc. (NASDAQ: CRDF) had its price target raised by analysts at Piper Sandler from $7.00 to $10.00. They now have an "overweight" rating on the stock.MarketBeat
- Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More [Yahoo! Finance]Yahoo! Finance
- CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study [Yahoo! Finance]Yahoo! Finance
- What's Going On With Cardiff Oncology Stock On Tuesday? [Yahoo! Finance]Yahoo! Finance
CRDF
Earnings
- 11/7/24 - Beat
CRDF
Sec Filings
- 12/18/24 - Form 4
- 12/17/24 - Form SCHEDULE
- 12/16/24 - Form 4
- CRDF's page on the SEC website